GlassScriptPhysician profile
Ryan W Day
NPI 1265796346
$3,647.99
in general payments reported to CMS, 2019-2025
11 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 77% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.17 · 2023: $1,852 · 2024: $352 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,620 · Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,620.27 |
| Food and Beverage | $984.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $2,620.27 | 2023-2025 | Organ Care System |
| Dilon Technologies, INC. | $435.01 | 2023-2024 | Hemoblast Bellows |
| Guard Medical INC. | $144.18 | 2023 | Npseal (5), Npseal Large, Npseal Medium |
| Astrazeneca Pharmaceuticals LP | $114.46 | 2024 | Imfinzi |
| Intercept Pharmaceuticals, INC. | $95.92 | 2022-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $78.53 | 2023-2025 | Prevymis, Zerbaxa, Dificid |
| Integra Lifesciences Corporation | $58.28 | 2024-2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.09 | 2023-2025 | Xifaxan |
| Veloxis Pharmaceuticals, INC. | $25.30 | 2023 | Envarsus |
| Shionogi INC | $22.24 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.